Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sulfasalazine, quantity: 500 mg - tablet, uncoated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; povidone; maize starch - ulcerative colitis and crohn's disease: adjunct in the treatment of ulcerative colitis with the usual supportive and dietary measures. for the management of severe, acute attacks of ulcerative colitis, rectal and systemic corticosteroid therapy appears to be clinically superior to sulfasalazine, but sulfasalazine may be more effective than corticosteroids in reducing the number of relapses in patients on maintenance therapy. in the treatment of active crohn's disease, especially in patients with colonic involvement. rheumatoid arthritis: salazopyrin en-tabs are indicated for rheumatoid arthritis which has failed to respond to non-steroidal anti-inflammatory drugs (nsaids).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sulfasalazine, quantity: 500 mg - tablet, enteric coated - excipient ingredients: white beeswax; macrogol 20000; carnauba wax; magnesium stearate; povidone; cellacefate; maize starch; propylene glycol; colloidal anhydrous silica; glyceryl monostearate; purified talc - ulcerative colitis and crohn's disease: adjunct in the treatment of ulcerative colitis with the usual supportive and dietary measures. for the management of severe, acute attacks of ulcerative colitis, rectal and systemic corticosteroid therapy appears to be clinically superior to sulfasalazine, but sulfasalazine may be more effective than corticosteroids in reducing the number of relapses in patients on maintenance therapy. in the treatment of active crohn's disease, especially in patients with colonic involvement. rheumatoid arthritis: salazopyrin en-tabs are indicated for rheumatoid arthritis which has failed to respond to non-steroidal anti-inflammatory drugs (nsaids).

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - sulfasalazine - tablets enteric coated - sulfasalazine 500 mg - sulfasalazine - sulfasalazine - for active rheumatoid arthritis which is not controlled by antiinflammatory drugs.ulcerative colitis, crohn's disease, pyoderma gangrenosum.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - sulfasalazine - tablets - sulfasalazine 500 mg - sulfasalazine - sulfasalazine - treatment of ulcerative colitis and crohn's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sulfasalazine 500mg (sulfasalazine 500 mg added as 535 mg sulfasalazine with povidone) - enteric coated tablet - 500 mg - active: sulfasalazine 500mg (sulfasalazine 500 mg added as 535 mg sulfasalazine with povidone) excipient: carnauba wax cellacefate colloidal silicon dioxide macrogol 20000 magnesium stearate povidone propylene glycol purified talc self-emulsifying glyceryl monostearate starch white beeswax - ulcerative colitis and crohn's disease adjunct in the treatment of ulcerative colitis with the usual supportive and dietary measures. for the management of severe, acute attacks of ulcerative colitis, rectal and systemic corticosteroid therapy appears to be clinically superior to sulfasalazine, but sulfasalazine may be more effective than corticosteroids in reducing the number of relapses in patients on maintenance therapy. in the treatment of active crohn's disease, especially in patients with colonic involvement. rheumatoid arthritis salazopyrin en tablets are indicated for rheumatoid arthritis which has failed to respond to nonsteroidal anti-inflammatory drugs (nsaids).

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sulfasalazine 500mg (sulfasalazine 500 mg added as 535 mg sulfasalazine with povidone) - tablet - 500 mg - active: sulfasalazine 500mg (sulfasalazine 500 mg added as 535 mg sulfasalazine with povidone) excipient: colloidal silicon dioxide magnesium stearate povidone pregelatinised maize starch - latest regulatory activity

Australia - English - Department of Health (Therapeutic Goods Administration)

sulfasalazine -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - sulfasalazine - gastro-resistant tablet - 500mg

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - sulphasalazine - enteric coated tablet - 500 mg - sulphasalazine 500 mg

Ireland - English - HPRA (Health Products Regulatory Authority)

pharmacia laboratories limited - sulfasalazine - suppositories - 500 milligram